Trial Profile

An Open-Label Extension Study of ISIS 721744 in Patients With Hereditary Angioedema

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 26 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Donidalorsen (Primary)
Indications Hereditary angioedema
Focus Adverse reactions
Acronyms OASIS-Plus
Sponsors Ionis Pharmaceuticals

Most Recent Events

24 Mar 2025 Status changed from active, no longer recruiting to completed.
20 Feb 2025 According to Ionis Pharmaceuticals media release, company will present data from the OASISplus Open-Label Extension Study at the 2025 American Academy of Allergy, Asthma & Immunology (AAAAI) / World Allergy Organization (WAO) Joint Congress in San Diego, California on March 2, 2025.
19 Feb 2025 Results data demonstrating an overall sustained mean reduction in HAE attack rates of 96% in patients treated up to three years with every four weeks or every eight weeks dosing were presented in the Ionis Pharmaceuticals Media Release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com